Today: 10 June 2026
Browse Category

NYSE:NVO 18 December 2025 - 6 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

The U.S. FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP-1 drug for chronic weight management, on Dec. 22. Novo Nordisk ADRs closed at $52.56 on Dec. 24, up 1.8% after the news. The company plans a U.S. launch in early January 2026. Trial data showed a mean weight loss of 16.6% for patients adhering to the regimen.
25 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

U.S. regulators have approved Novo Nordisk’s oral Wegovy pill for weight management and cardiovascular risk reduction, sending NVO shares higher earlier this week. Analysts are watching pricing and insurance coverage in the U.S., as well as competition in India ahead of 2026 generic launches. The pill is expected to reach U.S. patients in January. NVO stock traded in the low-$50s on Dec. 24.
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly shares closed down 0.45% at $1,071.64 on Tuesday after the FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP‑1 drug for chronic weight management in the U.S. Novo shares rose on the news, while Lilly stock traded flat in after-hours. Investors focused on the competitive impact of the new oral treatment on Lilly’s obesity franchise. Trading volume reached about 2 million shares.
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

U.S. regulators approved Novo Nordisk’s once-daily oral Wegovy pill for chronic weight management and cardiovascular risk reduction on Dec. 23, 2025. Novo shares rose about 9% in U.S. trading, with investors reacting to the company’s first-to-market status for a high-efficacy oral GLP-1 obesity drug. The FDA decision also lifted European healthcare stocks, pushing the STOXX 600 to a record high.
23 December 2025
·
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly shares traded near $1,076 after the FDA approved Novo Nordisk’s first daily oral Wegovy for obesity. Novo plans a U.S. launch in January 2026, beating Lilly’s own oral candidate, which remains under review. Novo shares rose on the news; Lilly slipped slightly. Analysts expect oral obesity drugs could reach 20% of the market by 2030.
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management in the U.S., marking the first oral GLP-1 agonist cleared for this use. Shares jumped on the news, lifting European healthcare stocks. The company reported 16.6% mean weight loss in trials when taken as prescribed. Novo plans to launch the pill in the U.S. in early January 2026.
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly shares closed up 0.47% at $1,076.48 Monday, then fell about 1% in after-hours trading after the FDA approved Novo Nordisk’s Wegovy weight-loss pill. Novo’s U.S. shares jumped roughly 6% following the news. The new oral semaglutide is the first FDA-cleared pill for obesity, with Novo saying it will launch early next year at $149 a month. Lilly’s own oral obesity drug, orforglipron, could be approved as soon as late March.
23 December 2025
····
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly shares closed up 1.45% at $1,056.88 Thursday after reporting positive Phase 3 results for its oral obesity drug orforglipron. Patients switching from injectable GLP-1 drugs maintained weight loss, with those from Wegovy averaging 0.9 kg change and those from Zepbound 5 kg. The stock held steady in after-hours trading. Detailed trial data will be released later.
18 December 2025
···
1 2 3 4 5 6 7

Stock Market Today

  • Marwyn Value Investors Limited Shares Major Stake Notification
    June 10, 2026, 6:28 AM EDT. On June 9, 2026, Marwyn Investment Management LLP notified a major interest in Marwyn Value Investors Limited, crossing the 18.92% voting rights threshold. The notification, filed on June 10, 2026, indicates 1,070,000 voting rights held via direct shares, representing a significant stake. The disclosure highlights the regulatory requirement for investors to report acquisitions of substantial voting rights, impacting control and shareholder influence. Marwyn Value Investors Limited is a non-UK issuer, with Pershing Securities Limited acting as the shareholder notifier. The transaction was completed in Jersey, underscoring transparency in shareholder positions for market participants and regulators.

Latest articles

US stock futures slip with CPI ahead as Iran oil risk stirs Fed worries

US stock futures slip with CPI ahead as Iran oil risk stirs Fed worries

10 June 2026
S&P 500, Nasdaq 100, and Dow futures fell sharply premarket as investors braced for the May CPI report, expected to show the fastest annual inflation since April 2023, with tech stocks hit hardest amid rising oil prices and fresh U.S.-Iran strikes, raising fears of persistent inflation and fewer Fed rate cuts.
Erie Insurance gains 15 spots to No. 308 on Fortune 500

Erie Insurance gains 15 spots to No. 308 on Fortune 500

10 June 2026
Erie Insurance jumped 15 spots to No. 308 on the 2026 Fortune 500 with $14.6 billion in revenue, easily clearing the $7.5 billion cutoff as the bar rose 5%, but analysts warn U.S. property-and-casualty insurers face softer pricing, more competition, and rising catastrophe risks, with 2026 premium growth forecast to slow and return on equity to ease after a strong 2025.
Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle Faces $600 Billion AI Bet as Traders Watch for Volatility

10 June 2026
Oracle shares slid nearly 3% to $205.81 ahead of Wednesday’s earnings, as investors await proof that its $553 billion AI cloud backlog can convert to revenue quickly enough to justify heavy data-center spending, with options pricing signaling an 11% stock swing after results.
DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

10 June 2026
DraftKings shares soared 11.34% to $27.59 after revealing a 24% month-over-month jump in annualized consumer volume to $1.3 billion and a 34% rise in total volume traded to $3.1 billion in its Predictions product for May, based on preliminary, unaudited data, outpacing a falling Nasdaq and spotlighting investor focus on the product’s revenue potential and DraftKings’ strategic push.
Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

10 June 2026
Micron shares fell 1.5% to $935.89 as the AI-chip rally cooled, despite bullish analyst calls and price targets up to $1,625; investors await the June 24 earnings report to see if tight memory chip supply and AI demand can sustain the stock’s trillion-dollar valuation amid broader market jitters and shifting sentiment.
Go toTop